CL2023001737A1 - Ésteres de ácido dicarboxílico para inducir un efecto analgésico - Google Patents

Ésteres de ácido dicarboxílico para inducir un efecto analgésico

Info

Publication number
CL2023001737A1
CL2023001737A1 CL2023001737A CL2023001737A CL2023001737A1 CL 2023001737 A1 CL2023001737 A1 CL 2023001737A1 CL 2023001737 A CL2023001737 A CL 2023001737A CL 2023001737 A CL2023001737 A CL 2023001737A CL 2023001737 A1 CL2023001737 A1 CL 2023001737A1
Authority
CL
Chile
Prior art keywords
dicarboxylic acid
analgesic effect
induce
acid esters
methods
Prior art date
Application number
CL2023001737A
Other languages
English (en)
Spanish (es)
Inventor
Izbicka Elzbieta
T Streeper Robert
Original Assignee
New Frontier Labs Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Frontier Labs Llc filed Critical New Frontier Labs Llc
Publication of CL2023001737A1 publication Critical patent/CL2023001737A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2023001737A 2020-12-16 2023-06-14 Ésteres de ácido dicarboxílico para inducir un efecto analgésico CL2023001737A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063126387P 2020-12-16 2020-12-16

Publications (1)

Publication Number Publication Date
CL2023001737A1 true CL2023001737A1 (es) 2024-01-19

Family

ID=81942874

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001737A CL2023001737A1 (es) 2020-12-16 2023-06-14 Ésteres de ácido dicarboxílico para inducir un efecto analgésico

Country Status (12)

Country Link
US (1) US11911358B2 (enExample)
EP (1) EP4262779A4 (enExample)
JP (1) JP7837335B2 (enExample)
KR (1) KR20230131182A (enExample)
CN (1) CN116829141A (enExample)
AU (1) AU2021400215A1 (enExample)
CA (1) CA3202461A1 (enExample)
CL (1) CL2023001737A1 (enExample)
CO (1) CO2023007903A2 (enExample)
IL (1) IL303751A (enExample)
MX (1) MX2023006728A (enExample)
WO (1) WO2022130288A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022022437A2 (pt) 2020-05-07 2023-01-03 Adorx Therapeutics Ltd Antagonistas do receptor a2a de adenosina
US20260048034A1 (en) 2024-08-15 2026-02-19 New Frontier Labs, Llc Compositions and methods for enhancing the efficacy of dicarboxylic acid esters, and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS539788A (en) * 1976-07-14 1978-01-28 Syntex Inc 55aloyll1*22dihydroo3hh pyroro *1*22a* pyroll11 carboxylic acid derivative
JPH07116026B2 (ja) * 1987-07-07 1995-12-13 株式会社資生堂 ジクロフェナックナトリウム含有乳化外用剤
JP2523428B2 (ja) * 1992-12-04 1996-08-07 エスエス製薬株式会社 消炎鎮痛ゲル製剤
US9265725B2 (en) * 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
JP2004300113A (ja) * 2003-04-01 2004-10-28 Nichiban Co Ltd 消炎鎮痛貼付剤
WO2006074379A2 (en) * 2005-01-07 2006-07-13 Azaya Therapeutics, Inc. Methods and compositions involving esters of azelaic acid and other dicarboxylic acids
US8822509B2 (en) * 2006-12-29 2014-09-02 The University Of Queensland Pain-relieving compositions and uses therefor
EP2219633A2 (en) * 2007-11-23 2010-08-25 Nectid, Inc. Tapentadol compositions
US20090326069A1 (en) * 2008-06-30 2009-12-31 Bltn, Llc Azelaic acid ester compositions and methods for diagnosing and treating tissue conditions using azelaic acid ester compositions and proteinaceous biomarkers
BRPI0901758A2 (pt) * 2009-05-28 2011-01-25 Cristalia Prod Quimicos Farm uso de telocinobufagina como analgésico no tratamento das dores aguda e crÈnica; composição farmacêutica contendo telocinobufagina e uso da mesma
US20120251525A1 (en) * 2009-06-30 2012-10-04 Streeper Robert T Method of utilizing azelaic acid esters to modulate communications mediated by biological molecules
EP3445354B8 (en) * 2016-04-20 2022-07-06 New Frontier Labs, LLC Azelaic acid esters in the treatment of insulin resistance
US20220023423A1 (en) * 2018-12-19 2022-01-27 Medrx Co., Ltd. Anti-Inflammatory Analgesic External Preparation
CN111544381B (zh) * 2020-05-12 2021-07-16 普霖贝利生物医药研发(上海)有限公司 一种包含壬二酸的皮肤局部给药组合物

Also Published As

Publication number Publication date
AU2021400215A9 (en) 2025-03-20
CN116829141A (zh) 2023-09-29
MX2023006728A (es) 2023-06-19
WO2022130288A1 (en) 2022-06-23
KR20230131182A (ko) 2023-09-12
EP4262779A4 (en) 2024-11-13
US11911358B2 (en) 2024-02-27
CA3202461A1 (en) 2022-06-23
AU2021400215A1 (en) 2023-07-06
US20220184023A1 (en) 2022-06-16
IL303751A (en) 2023-08-01
CO2023007903A2 (es) 2023-06-30
JP2023553642A (ja) 2023-12-25
EP4262779A1 (en) 2023-10-25
JP7837335B2 (ja) 2026-03-30

Similar Documents

Publication Publication Date Title
NI202100014A (es) Metodos para reducir el riesgo de eventos cardiovasculares en un sujeto
NI202100009A (es) Métodos para reducir la necesidad de revascu
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
MX394763B (es) Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina
CO2023007903A2 (es) Ésteres de ácido dicarboxílico para inducir un efecto analgésico
CO2019006291A2 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
MX2011008448A (es) Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
NI201300086A (es) Composicion de complejo oral que contiene ester de acido graso omega-3 e inhibidor de reductasa hmg-coa
CR11648A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
NI201100013A (es) Salicilatos acetilados con ácidos grasos y sus usos.
BR112014027204A2 (pt) conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos
AR085927A1 (es) Composiciones farmaceuticas intranasales de benzodiazepina
BR112013020167A2 (pt) melhoradores de permeação para formulações tópicas
BR112015020707A2 (pt) formulações transdermicas
NZ628079A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
CO2018002198A2 (es) Composiciones farmacéuticas que comprenden un compuesto oligomérico para modular la expresión de apolipoproteína (a)
MX390011B (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
CL2023001739A1 (es) Ésteres de ácidos dicarboxílicos para el tratamiento de enfermedades y padecimientos asociados con la toxina
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
UY35445A (es) Ésteres de testosterona de cadena larga lipoequilibrados para la administración oral
BR112013004714A2 (pt) "combinações de inibidores de hdac com fármacos de trombocitopenia e seus usos"
CO2023000194A2 (es) Administración de sulcardina para el tratamiento de fibrilación auricular aguda
GT201200295A (es) Combinacion de un aine y un aminoácido
TW201611830A (en) Pharmaceutical formulation for reducing bladder spasms and method of use thereof